Treprostinil (Remodulin) for Pulmonary Arterial Hypertension
Treprostinil sodium (tre prost' in il; Remodulin - United Therapeutics), a prostacyclin analogue, has been approved by the FDA for continuous subcutaneous (SC) treatment of patients with pulmonary arterial hypertension who have dyspnea on more than minimal exertion (NYHA Class II-IV)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Treprostinil (Remodulin) for Pulmonary Arterial Hypertension
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1139
Article Code: 1139b
Date: September 16, 2002
Volume: 44
Pages: 80-82
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1139
Article Code: 1139b
Date: September 16, 2002
Volume: 44
Pages: 80-82
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)